Skip to main
HROW

HROW Stock Forecast & Price Target

HROW Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 86%
Buy 14%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Harrow is expected to be successful in expanding their product line and reaching their sales goal of $250 million by 2027 through driving sales of existing products and acquiring new ones. They have obtained a new J-code for one of their drugs, contributing to projected revenue of $365 million in 2026, but face potential risks such as unexpected outcomes, regulatory uncertainty, and competition. The company remains focused on promoting their current products and turning interest into sales.

Bears say

Harrow is facing declining revenues due to non-recurring gross-to-net adjustments and an overall operating and net loss. While management expects to normalize these adjustments in the next quarter, the current guidance for 2026 reaffirms a relatively stagnant revenue forecast. In order to compete in the competitive and constantly advancing eyecare market, Harrow will need to acquire additional products to diversify their portfolio and maintain growth in the future.

HROW has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 86% of analysts recommend a Strong Buy, 14% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Harrow Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Harrow Health Inc (HROW) Forecast

Analysts have given HROW a Strong Buy based on their latest research and market trends.

According to 7 analysts, HROW has a Strong Buy consensus rating as of May 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $69.43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $69.43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Harrow Health Inc (HROW)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.